Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.
Edinburgh Innovations | Positive trial results for Kynos… ed.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ed.ac.uk Daily Mail and Mail on Sunday newspapers.
University of Edinburgh biotechnology spinout Kynos Therapeutics Ltd has announced that dosing is underway in a first in-human phase I trial of its lead drug candidate, KNS366.